2016 - Handbook Lymphoma
120 pág.

2016 - Handbook Lymphoma

DisciplinaHemato-oncologia79 materiais689 seguidores
Pré-visualização32 páginas
Handbook of Lymphoma
Anas Younes
Handbook of 
Anas Younes
Anas Younes
Memorial Sloan Kettering Cancer Center
New York, NY
Handbook of 
ISBN 978-3-319-08466-4 ISBN 978-3-319-08467-1 (eBook)
DOI 10.1007/978-3-319-08467-1
© Springer International Publishing Switzerland 2016
This work is subject to copyright. All rights are reserved by the Publisher, whether the whole 
or part of the material is concerned, speci\ufffdcally the rights of translation, reprinting, reuse of 
 illustrations, recitation, broadcasting, reproduction on micro\ufffdlms or in any other physical way, 
and transmission or information storage and retrieval, electronic adaptation, computer software, 
or by similar or dissimilar methodology now known or hereafter developed. 
The use of general descriptive names, registered names, trademarks, service marks, etc. in this 
publication does not imply, even in the absence of a speci\ufffdc statement, that such names are 
exempt from the relevant protective laws and regulations and therefore free for general use.
The publisher, the authors and the editors are safe to assume that the advice and information in 
this book are believed to be true and accurate at the date of publication. Neither the publisher 
nor the authors or the editors give a warranty, express or implied, with respect to the material 
contained herein or for any errors or omissions that may have been made.
Printed on acid-free paper
This Adis imprint is published by Springer Nature
The registered company is Springer International Publishing AG Switzerland
Project editor: Laura Hajba
Anas Younes, MD
Memorial Sloan Kettering Cancer Center
New York, NY
Connie Batlevi, MD, PhD 
Ahmet Dogan, MD
Neha Mehta-Shah, MD
Colette Owens, MD
Anastasios Stathis, MD
Editor and author biographies ix
Abbreviations xi
1 Introduction 1
Colette Owens and Anas Younes
Introduction 1
Risk factors 3
Diagnosis 4
Clinical presentation 5
Prognostic factors 7
References 9
2 Risk factors, etiology, and pathogenesis 11
Anastasios Stathis and Colette Owens
Risk factors and causes 11
Pathogenesis of non-Hodgkin lymphoma 15
Pathogenesis of Hodgkin lymphoma 18
References 19
3 World Health Organization classification 21
Anas Younes and Ahmet Dogan
References 25
4 Staging 27
Colette Owens and Anas Younes
Introduction 27
Biopsy 27
Assessment of disease stage 29
Lumbar puncture 30
Additional tests 30
Reference 31
5 Treatment overview 33
Anastasios Stathis
Goals of treatment 33
Pre-treatment evaluation 33
Overview of types of treatment 34
After treatment 41
New research and emerging treatment options 41
References 42
6 Treatment of B-cell lymphomas 45
Anastasios Stathis and Ahmet Dogan
Diffuse large B-cell lymphoma 45
Follicular lymphoma 50
Mantle cell lymphoma 53
Small B-cell lymphocytic lymphoma and chronic lymphocytic leukemia 53
Marginal zone lymphoma 54
Burkitt\u2019s lymphoma 55
References 55
7 Treatment of T-cell lymphomas 59
Neha Mehta-Shah and Ahmet Dogan
Overview of T-cell lymphomas 59
Approach to treatment of systemic T-cell lymphomas 63
Approach to treatment of cutaneous 
T-cell lymphomas 72
References 76
8 Treatment of Hodgkin lymphoma 83
Anas Younes
Introduction 83
Early stage Hodgkin lymphoma 83
Advanced stage Hodgkin lymphoma 85
Management of patients with relapsed and refractory Hodgkin lymphoma 87
Management of patients with relapsed Hodgkin lymphoma after 
stem cell transplant 88
References 91
9 Management of human immunodeficiency 
virus-associated lymphomas 95
Connie Batlevi
Introduction 95
Antiretroviral and supportive therapy 96
Systemic human immunodeficiency virus-associated 
non-Hodgkin lymphoma 96
Other types of non-Hodgkin lymphoma 109
Human immunodeficiency virus-associated Hodgkin lymphoma 109
References 110
CO N T E N T S \u2022 V I I
Editor and author biographies
Anas Younes, MD, is the Chief of the 
Lymphoma Service at Memorial Sloan 
Kettering Cancer Center and Professor of 
Medicine at Weill-Cornell Medical College, 
New York, NY, USA. He has extensive experi-
ence in clinical and translational research in 
lymphoma. He was the Principal Investigator 
of the MD Anderson Cancer Center Lymphoma 
SPORE grant, and is currently the Principal 
Investigator of the Memorial Sloan Kettering Cancer Center Lymphoma 
SPORE grant. He has lead more than 60 clinical trials in lymphoma. He has 
lead, in collaboration with colleagues from around the world, the pivotal 
trials that resulted in the US FDA approval of brentuximab vedotin and 
nivolumab for the treatment of patients with relapsed Hodgkin lymphoma. 
He has published more than 250 papers on lymphoma.
Connie Batlevi, MD, PhD, Assistant Professor, Lymphoma Service, 
Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ahmet Dogan, MD, Chief, Hematopathology, Memorial Sloan Kettering 
Cancer Center, New York, NY, USA.
Neha Mehta-Shah, MD, Assistant Professor, Division of Oncology, 
Washington University School of Medicine, St Louis, MO, USA.
Colette Owens, MD, Instructor, Department of Medicine, Memorial Sloan 
Kettering Cancer Center, New York, NY, USA.
Anastasios Stathis, MD, Oncology Institute of Southern Switzerland, 
Ospedale San Giovanni, Bellinzona, Switzerland.
aa-IPI Age-adjusted IPI
ABC Activated B-cell like
ABVD Doxorubicin, bleomycin, vinblastine 
and dacarbazine 
ADC Antibody drug-conjugate
AIDS Acquired immunodeficiency syndrome
ALCL Anaplastic large cell lymphoma
AMC AIDS Malignancy Consortium
AMP Doxorubicin, ranimustine, and prednisone
ASCT Autologous stem cell transplantation
ATLL Adult T-cell leukemia/lymphoma
BCCA British Columbia Cancer Agency
BCR B-cell receptor
BEACOPP Bleomycin, etoposide, doxorubicin, 
cyclophosphamide, vincristine, procarbazine, 
and prednisone
bFGF Basic fibroblast growth factor
BL Burkitt\u2019s lymphoma
BTK Bruton\u2019s tyrosine kinase
cHL Classical Hodgkin lymphoma
CHOP Cyclophosphamide, doxorubicin, vincristine, 
and prednisone
CI Confidence interval
CLL Chronic lymphocytic leukemia
CODOX-M/IVAC Cyclophosphamide, doxorubicin, vincristine, 
methotrexate, etoposide, ifosfamide, and cytarabine
COMPLETE Comprehensive Oncology Measures for Peripheral 
T-Cell Lymphoma Treatment
CNS Central nervous system
COO Cells of origin
CR Complete response
CSF Cerebrospinal fluid
CT Computed tomography
CTCL Cutaneous T-cell lymphomas
CVP Cyclophosphamide, vincristine, and prednisolone
DA-EPOCH-R Dose-adjusted toposide, doxorubicin, and 
cyclophosphamide with vincristine, prednisone, 
and rituximab 
DFS Disease-free survival
DHAP Dexamethasone, cytarabine, and cisplatinum
DLBCL Diffuse large B-cell lymphoma 
EATL Enteropathy-associated T-cell lymphoma
EBMT European Group for Blood and Marrow 
EBV Epstein-Barr virus
ECOG Eastern Cooperative Oncology Group
ECP Extracorporal photopheresis
EFS Event-free survival
ENKTL Extranodal NK/T-cell lymphoma
EORTC European Organisation for Research and Treatment 
of Cancer
ESR Erythrocyte sedimentation rate
FC Flow cytometry
FFP Freedom from progression
FISH Fluorescence in situ hybridization 
FL Follicular lymphoma
FLIPI Follicular lymphoma International Prognostic Index
GC Germinal center
GCB GCB-cell like
GELA Groupe d'Etude des Lymphomes de l'Adulte
GELF Groupe d\u2019Etude des Lymphomes Folliculaires
GEP Gene-expression profiling
GHSG German Hodgkin Lymphoma Study Group
G-CSF Granulocyte-colony stimulating factor
GVL Graft versus lymphoma
H&E Hematoxylin and eosin
HAART Highly active antiretroviral therapy